Skip to main content
SpringerLink
Log in

The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Thioredoxin-interacting protein (Txnip), an inhibitor of thioredoxin (Trx), increases in diabetic nephropathy and promotes oxidative stress. The angiotensin II (Ang II) receptor blocker telmisartan may protect renal function in diabetic models and patients via multiple effects including antioxidation. However, its mechanism has not been fully elucidated, and its relationship to Txnip remains unclear. Aim: This study aimed to investigate whether telmisartan ameliorates oxidative stress by regulating Txnip and Trx expression in Type 2 diabetic rat kidneys and explore the possible relationship between renoprotection by telmisartan and Txnip. Methods: Twenty-one rats were equally divided into control (C), streptozotocin-induced diabetic (D), and telmisartan-treated diabetic (T) groups. Txnip and Trx expression in rat kidneys was analyzed by immunohistochemistry, RTPCR, and western blot. Peroxisome proliferator-activated receptor-γ(PPARγ), NADPH oxidase activity, and parameters of renal function and oxidative stress were also measured. Results: Trx and PPARγ were significantly decreased, and Txnip expression and NADPH oxidase activity markedly increased, in the D and T groups compared to the C group. After telmisartan treatment, Trx and PPARγ were upregulated, while Txnip expression and NADPH oxidase activity were down-regulated. Parameters of renal function and oxidative stress were improved by telmisartan. Conclusion: Telmisartan ameliorates oxidative stress and protects renal function in Type 2 diabetic rat kidneys. The downregulation of Txnip by telmisartan may be associated with PPARγ activation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57: 1446–51.

    Article  PubMed  Google Scholar 

  2. Advani A, Gilbert RE, Thai K, et al. Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 2009, 20: 730–41.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Hamada Y, Miyata S, Nii-Kono T, et al. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant 2007, 22: 1547–57.

    Article  PubMed  Google Scholar 

  4. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004, 279: 30369–74.

    Article  PubMed  Google Scholar 

  5. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 2006, 281: 21884–91.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Fang S, Jin Y, Zheng H, et al. High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway. Mol Cell Biochem 2011, 347: 175–82.

    Article  PubMed  Google Scholar 

  7. Qi W, Chen X, Gilbert RE, et al. High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol 2007, 171: 744–54.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1–7) Mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res 2011, 45: 575–84.

    Article  PubMed  Google Scholar 

  9. Nishiyama A, Nakagawa T, Kobori H, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens 2008, 26: 1849–59.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Hasegawa G, Fukui M, Hosoda H, et al. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats. Eur J Pharmacol 2009, 605: 164–9.

    Article  PubMed  Google Scholar 

  11. Nakayama M, Inoguchi T, Sonta T, et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 2005, 332: 927–33.

    Article  PubMed  Google Scholar 

  12. Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 2008, 45: 619–26.

    Article  PubMed  Google Scholar 

  13. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43: 993–1002.

    Article  PubMed  Google Scholar 

  14. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007, 35: 482–9.

    Article  PubMed  Google Scholar 

  15. Watanabe M, Inukai K, Sumita T, et al. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med 2010, 49: 1843–7.

    Article  PubMed  Google Scholar 

  16. Qi W, Chen X, Holian J, Tan CY, Kelly DJ, Pollock CA. Transcription factors Kruppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol 2009, 175: 1858–67.

    Article  PubMed Central  PubMed  Google Scholar 

  17. Billiet L, Furman C, Larigauderie G, et al. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J Cell Physiol 2008, 214: 183–91.

    Article  PubMed  Google Scholar 

  18. Oka S, Masutani H, Liu W, et al. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology 2006, 147: 733–43.

    Article  PubMed  Google Scholar 

  19. Chutkow WA, Birkenfeld AL, Brown JD, et al. Deletion of the alpha-arrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 2010, 59: 1424–34.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Yang XY, Sun L, Xu P, et al. Effects of salvianolic acid A on plantar microcirculation and peripheral nerve function in diabetic rats. Eur J Pharmacol 2011, 665: 40–6.

    Article  PubMed  Google Scholar 

  21. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55: 367–74.

    Article  PubMed  Google Scholar 

  22. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002, 277: 19952–60.

    Article  PubMed  Google Scholar 

  23. Zhang L, Tu H, Li YL. Angiotensin II enhances hyperpolarization-activated currents in rat aortic baroreceptor neurons: involvement of superoxide. Am J Physiol Cell Physiol 2009, 298: C98–106.

    Article  PubMed  Google Scholar 

  24. Yamawaki H, Berk BC. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 2005, 14: 149–53.

    Article  PubMed  Google Scholar 

  25. Panchapakesan U, Sumual S, Pollock CA, et al. PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005, 289: F1153–8.

    Article  PubMed  Google Scholar 

  26. Cha DR, Zhang X, Zhang Y, et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007, 56: 2036–45.

    Article  PubMed  Google Scholar 

  27. Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and Type 2 diabetes patients. Mol Cell Biochem 2009, 324: 173–81.

    Article  PubMed  Google Scholar 

  28. Kuppan G, Balasubramanyam J, Monickaraj F, Srinivasan G, Mohan V, Balasubramanyam M. Transcriptional regulation of cytokines and oxidative stress by gallic acid in human THP-1 monocytes. Cytokine 2010, 49: 229–34.

    Article  PubMed  Google Scholar 

  29. Saitoh Y, Hongwei W, Ueno H, Mizuta M, Nakazato M. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009, 35: 392–7.

    Article  PubMed  Google Scholar 

  30. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000, 267: 6102–9.

    Article  PubMed  Google Scholar 

  31. Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G. Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 2009, 52: 636–44.

    Article  PubMed  Google Scholar 

  32. Saitoh Y, Hongwei W, Ueno H, et al. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009, 35: 392–7.

    Article  PubMed  Google Scholar 

  33. Storka A, Vojtassakova E, Mueller M, et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008, 38: 820–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China

    J. Wu, H. Lin, D. Liu PhD, J. Liu, N. Wang, X. Mei, J. Sun & G. Yang

  2. Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    X. Zhang

Authors
  1. J. Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Liu PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X. Mei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. X. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Liu PhD.

Additional information

J. Wu and H. Lin contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, J., Lin, H., Liu, D. et al. The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein. J Endocrinol Invest 36, 453–459 (2013). https://doi.org/10.3275/8764

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/8764

Key-words

Search

Navigation